KPTI
- Karyopharm Therapeutics Inc.
()
Overview
Company Summary
Karyopharm Therapeutics Inc., also known as KPTI, is a biopharmaceutical company that specializes in the development and commercialization of novel drugs to treat cancer and other diseases. The company focuses on developing small molecule drugs that target specific proteins within the cell nucleus, with the goal of modulating the function of these proteins to treat various diseases.
Karyopharm's core technology revolves around selective inhibition of nuclear transport. Nuclear transport is a critical process in cell biology that controls the movement of macromolecules, including proteins and genetic material, between the nucleus and the cytoplasm. Dysregulation of nuclear transport is associated with several diseases, including cancer, autoimmune disorders, and certain neurological conditions.
The company's lead product is XPOVIO� (selinexor), which was approved by the U.S. Food and Drug Administration (FDA) in 2019 as a treatment for relapsed or refractory multiple myeloma, a type of blood cancer. XPOVIO works by inhibiting XPO1, an essential protein involved in exporting tumor-suppressor proteins out of the nucleus, thereby blocking cancer cell growth.
Apart from multiple myeloma, Karyopharm is actively exploring the potential of XPOVIO in other types of cancer and is conducting clinical trials to evaluate its efficacy in various solid tumors and hematologic malignancies.
Additionally, Karyopharm has a robust pipeline of other drug candidates in various stages of development. These candidates are designed to target different proteins involved in nuclear transport and other key cellular processes to address unmet medical needs in oncology and other therapeutic areas.
Overall, Karyopharm Therapeutics is dedicated to developing innovative treatments that target the cellular mechanisms underlying diseases like cancer, with the aim of improving patient outcomes and quality of life.